首页>
外国专利>
MONO AND COMBINATION THERAPY OF M1/M4 AGONIST (SABCOMELINE) FOR TREATMENT OF NEGATIVE SYMPTOMS OF SCHIZOPHRENIA
MONO AND COMBINATION THERAPY OF M1/M4 AGONIST (SABCOMELINE) FOR TREATMENT OF NEGATIVE SYMPTOMS OF SCHIZOPHRENIA
展开▼
机译:M1 / M4激动剂(SABCOMELINE)的单反和联合疗法治疗精神分裂症的阴性症状
展开▼
页面导航
摘要
著录项
相似文献
摘要
The invention relates to the use of a functional muscarinic M1/M4 receptor agonist or a pharmaceutically acceptable salt thereof for the treatment of negative symptoms of schizophrenia. It also relates to adjunctive and simultaneous combination therapies for the treatment of negative symptoms of schizophrenia in which the functional muscarinic M1/M4 receptor agonist or a pharmaceutically acceptable salt thereof, in particular sabcomeline or a pharmaceutically acceptable salt thereof and at least one neuroprotective agent, neuroleptic and/or atypical antipsychotic agent are administered adjunctively or simultaneously. The invention also provides methods of treatment of the negative symptoms of schizophrenia utilising such therapies and such adjunctive or simultaneous therapeutic combination therapies, therapeutic combinations for use therein and pharmaceutical compositions comprising them.
展开▼